Abstract: The present application describes deuterium-enriched sunitinib, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.
Abstract: The present application describes deuterium-enriched maraviroc, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.
Abstract: The present application describes deuterium-enriched tolterodine, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.
Abstract: The present application describes deuterium-enriched fesoterodine, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.
Abstract: The present application describes deuterium-enriched linezolid, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.
Abstract: The present application describes deuterium-enriched amlodipine, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.
Abstract: The present application describes deuterium-enriched lasofoxifene, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.
Abstract: The present application describes deuterium-enriched doxazosin, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.
Abstract: The present application describes deuterium-enriched cetirizine, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.
Abstract: The present application describes deuterium-enriched dalbavancin, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.
Abstract: The present application describes deuterium-enriched tiotropium, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.
Abstract: The present application describes deuterium-enriched azithromycin, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.
Abstract: The present application describes deuterium-enriched sertraline, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.
Abstract: The present application describes deuterium-enriched fluconazole, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.
Abstract: The present application describes deuterium-enriched PF-184298, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.
Abstract: The present application describes deuterium-enriched indiplon, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.
Abstract: The present application describes deuterium-enriched tipranavir, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.
Abstract: The present application describes deuterium-enriched anidulafungin, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.
Abstract: The present application describes deuterium-enriched pregabalin, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.
Abstract: The present application describes deuterium-enriched irinotecan, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.